Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSK | P43235 | 10/20 | 0.34 |
| ▸ | CTSS | P25774 | 5/20 | 0.32 |
| ▸ | CTSL | P07711 | 4/20 | 0.32 |
| ▸ | CTSB | P07858 | 2/20 | 0.32 |
| ▸ | PYGL | P06737 | 1/20 | 0.31 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6405796 | 1.00 | CTSK (0.34) | CTSKCTSSCTSLCTSBPYGL | |
| SCHEMBL5636940 | 0.86 | CTSL (0.42) | CTSKCTSSCTSLCTSB | |
| SCHEMBL5636936 | 0.86 | CTSL (0.42) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6605332 | 0.79 | CTSK (0.46) | CTSKCTSSCTSLCTSB | |
| SCHEMBL4908344 | 0.76 | CTSK (0.40) | CTSKCTSSCTSLCTSB | |
| SCHEMBL3905825 | 0.70 | CTSS (0.47) | CTSKCTSSCTSLCTSB | |
| SCHEMBL25276966 | 0.69 | HTT (0.40) | LMNA | |
| SCHEMBL25276967 | 0.69 | HTT (0.40) | LMNA | |
| SCHEMBL14583259 | 0.68 | CTSS (0.65) | CTSKCTSSCTSLCTSB | |
| SCHEMBL6650575 | 0.67 | CTSK (0.64) | CTSKCTSSCTSLCTSB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | SMITHKLINE BEECHAM CORPORATION | 2005-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050107616-A1 | Alpha-ketoamide derivatives as cathepsin k inhibitors | CTSK, CTSE, CTSZ | CTSK 1/4885CTSS 6/4885CTSL 12/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.